newsfilter
← Latest News
GlobeNewswire·

Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights

Highlights Phase 1 IMMUNICY-1 trial demonstrated encouraging data to date for CYAD-211 including a good tolerability profile and evidence of clinical activity in relapsed/refractory multiple myeloma (r/r MM) patients Investigation ongoing of finding